Phacilitate Leaders World

Welcome to Phacilitate Leaders World 2019

Welcome to Phacilitate Leaders World 2019

The world’s number 1 partnering event for advanced therapies

We believe that through strong partnerships and collaboration, anything can be achieved. That’s why in 2019 we are going to facilitate our biggest event to date that will help improve, disrupt and drive the future of advanced therapies.    

Phacilitate Leaders World 2019 will host more speakers, more sessions and more networking opportunities than ever seen before at a Phacilitate show. Over 300 speakers will be taking the stage to inspire you through new and innovative session formats and you’ll be sure to make new friends in the industry as we welcome over 2000 attendees through the door. 

Learn how to collaborate more effectively to advance the industry towards its common goal of delivering transformative therapeutic solutions that are accessible to all patients.

Check out the 2018 highlights here

Testimonials
  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Anne-Virginie Eggimann
    bluebird bio
  • Great program, great people, great venue.
    Klaus Kühlcke
    EUFETS GmbH
  • Dynamic, interesting and highly interactive event that promotes exchange and networking in highly specialized field of gene therapy.
    Nathalie Clement
    Powell Gene Therapy Center, University of Florida
  • Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field.
    Dr James Trager
    Dendreon
  • It was all business. I’ve never been to an event where over 80% of the conversations I had were constructive to my business objectives.
    Kurt Gielen
    Chemelot Campus B.V.
  • Great way to expand network with global experts in cell and gene therapy who are facing similar challenges.
    Steven Goodman
    GSK